T lymphocyte cell therapy - TC BioPharm

Drug Profile

T lymphocyte cell therapy - TC BioPharm

Alternative Names: Gamma-delta T cell therapy; Immunicell

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TC BioPharm
  • Developer Medinet; TC BioPharm
  • Class Antineoplastics; Cell therapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Malignant melanoma; Non-small cell lung cancer; Renal cancer
  • No development reported Hepatocellular carcinoma

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Hepatocellular carcinoma(Second-line therapy or greater) in Japan (Parenteral, Infusion)
  • 31 Mar 2016 Medinet completes a clinical trial in Hepatocellular carcinoma (Second-line therapy or greater) in Japan (UMIN000011184)
  • 01 Dec 2015 Phase-II/III clinical trials in Malignant melanoma (Second-line therapy or greater) in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top